• Replimune published final Phase 1 first-in-human results for RP2, an intratumoral oncolytic HSV-1 immunotherapy, alone or with nivolumab.
• Safety profile described as well tolerated, with no unexpected toxicity in the nivolumab combination; no grade 4-5 treatment-related adverse events reported.
• Objective response rate was 19% on RP2 monotherapy (n=21) versus 19.1% on RP2 plus nivolumab (n=47); disease control 42.9% versus 48.9%.
• Median duration of response was not reached on monotherapy; 22.1 months on combination therapy, supporting durability in heavily pretreated solid tumors.
• Program advanced into a randomized Phase 2/3 trial of RP2 plus nivolumab in metastatic uveal melanoma (NCT06581406).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on May 31, 2026, and is solely responsible for the information contained therein.